2019年6月10日新澤西州Freehold——國際領先的細胞生物技術公司Avalon Globocare（納斯達克：AVCO）今天宣布，該公司在臨床級幹細胞外泌體的生產標準化方面完成了重要里程碑。這一進展是公司之前宣布的與康奈爾醫學院（Weill Cornell Medicine） Yen-Michael Hsu教授聯合開發項目的直接成果。該標準化流程是在康奈爾醫學院cGMP認證的細胞實驗室內共同開發和操作的，該實驗室同時也具備細胞治療認證基金會（FACT）、美國血庫協會（AABB）、CAP以及CLIA的認證。
Avalon將於2019年6月15日第二屆中國成都國際醫美產業大會（亞洲最大行業會議）中，發布其基於外泌體的產品計劃，包括具有知識產權的臨床級外泌體添加成分（ “ACTEX“）的系列護膚及疤痕修復產品。除了該產品，Avalon同時還在推進其他臨床級幹細胞外泌體的製備標準化，包括針對血管/骨科再生和纖維化疾病治療的AVA-202、AVA-203等臨床方案。
Avalon GloboCare的CEO兼總裁David Jin博士表示： “很高興我們完成了外泌體項目中如此重要的發展里程碑，我們期待通過這一進展，能進一步加速我們基於外泌體的臨床應用，並推動一系列外泌體產品的商業化。”
Avalon GloboCare Corp.（NASDAQ: AVCO）是一家國際領先的細胞技術開發公司，致力於開發和轉化具有創新性、變革性的外泌體和細胞治療技術。 Avalon也提供戰略諮詢和技術合作服務，以協助促進其客戶在技術開發領域的發展，提高其在本國和全球醫療市場的競爭力。通過子公司GenExosome Technologies Inc.和Avactis Biosciences Inc.，Avalon在基於外泌體的診斷(“液體活檢”) 、細胞免疫治療(包括CAR-T/CAR-NK) 和再生醫學領域建立了領先地位。
Certain statements contained in this press release may constitute “forward-looking statements.” Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company’s views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of the press release.
